(E)-ethyl 2-(hydroxyimino)-3-oxobutanoate | 66508-94-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (E)-ethyl 2-(hydroxyimino)-3-oxobutanoate
• 英文别名: ethyl (2E)-2-hydroxyimino-3-oxobutanoate
• CAS: 66508-94-9
• 化学式: C₆H₉NO₄
• 分子量: 159.142
• InChiKey: IACSYDRIOYGJNH-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.03
• 重原子数：
  11.0
• 可旋转键数：
  3.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.96
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 2-(hydroxyimino)-3-oxobutanoate 在 溶剂黄146 、 锌 作用下， 反应 4.33h， 生成 2-(4-ethylphenyl)-5-methyloxazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] NOVEL OXAZOLE COMPOUNDS AS β-CATENIN MODULATORS AND USES THEREOF
  [FR] NOUVEAUX COMPOSÉS OXAZOLES POUVANT ÊTRE UTILISÉS COMME MODULATEURS DE LA Β-CATÉNINE ET LEURS UTILISATIONS

  摘要：

  根据公式I提供的噁唑化合物可作为Wnt通路的抑制剂，专门针对稳定的β- cat活性。这些化合物可制备为药物组合物，并可用于哺乳动物，包括人类的预防和治疗多种疾病，例如癌症以及与Wnt通路功能障碍相关的其他疾病，包括肺纤维化。

  公开号：

  WO2016081451A1
• 作为产物：
  描述：

  乙酰乙酸乙酯 在 溶剂黄146 、 sodium nitrite 作用下， 生成 (E)-ethyl 2-(hydroxyimino)-3-oxobutanoate
  参考文献：
  名称：

  Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

  摘要：

  该发明提供了在治疗2型糖尿病中有用的药物化合物。这些化合物具有优势，因为它们可以被代谢药物解毒系统迅速代谢。特别地，设计了包含酯基的噻唑烷二酮类似物的化合物。该发明还涉及治疗疾病的方法，如糖尿病，包括给予经设计为能够被血清或细胞内酯酶代谢的化合物的治疗有效组合物。还教授了含酯基的噻唑烷二酮类似物的药物组合物。

  公开号：

  US20030236227A1

文献信息

• [EN] OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS<br/>[FR] OXADIAZOLONES EN TANT QU'INHIBITEURS DE CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018096159A1

  公开（公告）日：2018-05-31

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  该发明涉及式(I)的化合物及其药用可接受的盐。此外，本发明涉及制备方法和使用式(I)的化合物的方法，以及含有这种化合物的药物组合物。这些化合物可能在治疗由TRPA1介导的疾病和症状，如疼痛方面有用。
• [EN] BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME<br/>[FR] COMPOSÉS ÉMISSIFS CYCLIQUES CONTENANT DU BORE ET FILM DE CONVERSION DE COULEUR LES CONTENANT
  申请人：NITTO DENKO CORP

  公开号：WO2021146380A1

  公开（公告）日：2021-07-22

  The present disclosure relates to novel photoluminescent complex comprising a BODIPY moiety covalently bonded to a blue light absorbing moiety, and a color conversion film, a back-light unit using the same.

  本公开涉及一种新型的光致发光配合物，该配合物包括一个与蓝色光吸收基团共价键连接的BODIPY部分，以及使用该配合物的色转换膜和背光单元。
• PROCESS OF FORMING A PYRROLE COMPOUND
  申请人：Zhong Guofu

  公开号：US20110124881A1

  公开（公告）日：2011-05-26

  Disclosed is a process of forming a pyrrole compound. The process comprises contacting an α-carbonyl oxime compound 1 and an α,β-unsaturated aldehyde 2 R 1 and R 2 in compound 1 are independently selected from the group consisting of H, a silyl-group, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group, and an arylalicyclic group. The aliphatic, alicyclic, aromatic, arylaliphatic, and arylalicyclic groups comprise 0 to about 3 heteroatoms selected from the group N, O, S, Se and Si. R 3 in aldehyde 2 is selected from the group consisting of H, a silyl-group, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group, and an arylalicyclic group. The aliphatic, alicyclic, aromatic, arylaliphatic, and arylalicyclic groups comprise 0 to about 3 heteroatoms selected from the group N, O, S, Se and Si. The α-carbonyl oxime compound 1 an the α,β-unsaturated aldehyde 2 are contacted in a suitable solvent in the presence of a secondary amine. The compounds are contacted for a sufficient period of time to allow the formation of an N-hydroxypyrrole compound 3

  揭示了一种形成吡咯化合物的过程。该过程包括将α-羰基肟化合物1与α，β-不饱和醛2接触。化合物1中的R1和R2分别独立地选自H、硅基团、脂肪基、脂环基、芳香基、芳基脂肪基和芳基脂环基组成的群。脂肪、脂环、芳香、芳基脂肪基和芳基脂环基包括0到约3个来自N、O、S、Se和Si组成的杂原子。醛2中的R3选自H、硅基团、脂肪基、脂环基、芳香基、芳基脂肪基和芳基脂环基组成的群。脂肪、脂环、芳香、芳基脂肪基和芳基脂环基包括0到约3个来自N、O、S、Se和Si组成的杂原子。在适当的溶剂中，在次胺的存在下，将α-羰基肟化合物1和α，β-不饱和醛2接触。这些化合物接触一段足够的时间以允许形成N-羟基吡咯化合物3。
• [EN] 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF<br/>[FR] UTILISATION DE DÉRIVÉS 2-PHÉNYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE COMME INHIBITEURS DE PHOSPHODIESTÉRASE ET LEURS UTILISATIONS
  申请人：TOPADUR PHARMA AG

  公开号：WO2017085056A1

  公开（公告）日：2017-05-26

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(0)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8=N-OR9, CR8=N-NR10R11, CR8=NR12 or CR8=N-ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2NR13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said heterocyclic ring are independently optionally substituted by C1-C3alkyl, F; R8 is H, CH3 or C2H5; R9: H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R10 and R11 are each independently H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl;i or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with C1-C3 alkyl; R12 is C1-C3 alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R13 and R14 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6Cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R15; R15 is C1-C6alkyl optionally substituted with halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR16, NR17R18, C=NR19, or with a tetrazole group which is optionally substituted with C1-C3alkyl; or a heteroaryl ring which is optionally substituted with F, wherein the at least one heteroatom of said heteroaryl ring is nitrogen; R16 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR17R18, or with a heteroaryl ring, wherein the at least one heteroatom of said heteroaryl ring is nitrogen, and wherein preferably said heteroaryl ring is selected from pyrrolidine, piperidine, piperazine, morpholine, pyrrole, and imidazole, wherein nitrogen atom is directly bound to C1-C4 alkyl; R17 and R18 are each independently H or C1-C4alkyl optionally substituted with ONO, ONO2; R19 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6Cycloalkyl; and their use in methods of treating or preventing a disease alleviated by inhibition of PDE-5 in a human or in a non-human mammal.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐、溶剂或水合物，其中R1是C1-C3烷基，可选择地取代为F，C3-C6环烷基，C1-C3烷氧基；X代表键或C1-C3烷基，可选择地取代为OH，ONO，ONO2；R2是H，OH，ONO，ONO2，C（O）OH，C（O）OC1-C3烷基，CHO，CN，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（0）N（R6）OR7，S（O0-2）C1-C3烷基，CR8=N-OR9，CR8=N-NR10R11，CR8=NR12或CR8=N-ONO2；R3是C1-C6烷基，可选择地取代为F，OH，ONO，ONO2，C1-C3烷氧基，C3-C6环烷基；C3-C6环烷基，C2-C6烯基，C2-C6炔基；R4是C1-C6烷基，可选择地取代为C3-C6环烷基，C1-C6烷氧基，F，ONO，ONO2；C2-C6烯基，C2-C6炔基，C3-C6环烷基；R5是H，SO2NR13R14，NHSO2NR13R14；R6是H或C1-C3烷基；R7是H，C1-C3烷基，C1-C3烷氧基，C1-C3烷基取代苯基，苄基或杂环戒指，其中所述苯基，苄基或所述杂环戒指可选择地取代为C1-C3烷基，F；R8是H，CH3或C2H5；R9：H，C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3烷基，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；R10和R11各自独立地是H，C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；或与它们连接的氮原子一起形成杂环戒指，其中优选地所述杂环戒指选自氮杂环丙烷，氮杂环戊烷，吡咯烷，哌啶，吗啉，哌嗪和同哌嗪，其中所述杂环戒指可选择地取代为C1-C3烷基；R12是C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3烷基，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；R13和R14各自独立地是H或C1-C6烷基，可选择地取代为F，OH，ONO，ONO2，COOH，C1-C3烷氧基，C3-C6环烷基；或与它们连接的氮原子一起形成杂环戒指，其中优选地所述杂环戒指选自氮杂环丙烷，氮杂环戊烷，吡咯烷，哌啶，吗啉，哌嗪，2,5-二氮杂双环[2,2,1]庚烷和3,7-二氮杂双环[3,3,0]辛烷，其中所述杂环戒指可选择地取代为R15；R15是C1-C6烷基，可选择地取代为卤素，OH，ONO，ONO2，C1-C3烷氧基，C1-C3卤代烷氧基，COOR16，NR17R18，C=NR19，或与一个四唑基团取代，该四唑基团可选择地取代为C1-C3烷基；或一个杂芳环，可选择地取代为F，其中所述杂芳环的至少一个杂原子是氮；R16是H，或C1-C4烷基，可选择地取代为F，OH，ONO，ONO2，NR17R18，或与一个杂芳环取代，其中所述杂芳环的至少一个杂原子是氮，优选地所述杂芳环选自吡咯烷，哌啶，哌嗪，吗啉，吡咯，咪唑，其中氮原子直接连接到C1-C4烷基；R17和R18各自独立地是H或C1-C4烷基，可选择地取代为ONO，ONO2；R19是C1-C4烷基，可选择地取代为F，ONO，ONO2；C3-C6环烷基；以及它们在治疗或预防人类或非人类哺乳动物中通过抑制PDE-5缓解的疾病的方法中的使用。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS OXAZOLE ANTAGONISTES DES RÉCEPTEURS D'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015018029A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述氧唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。